Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Strategies toward regenerative medicine
- The small molecule approach
- Synthetic small molecules controlling cell fate
- HTS identified novel pro-survival compounds
- E-cadherin is required for Tzv’s activity
- Tzv stabilizes E-cadherin in ECM-free condition
- Rho-ROCK-myosin axis
- Importance of cell-cell and cell-ECM interactions
- Adhesion mechanisms control stem cell fate
- Strategies for reprogramming somatic cells
- Small molecules replacing TFs
- hiPSCs reprograming using small molecules
- Full developmental potential of Oct4-hiPSC lines
- PS48 facilitates metabolic switch
- PS48’s reprogramming depends on glycolysis
- PS48 induces glycolysis
- Cell-activation signal-directed reprogramming
- Fibroblasts to cardiac cells CASD reprogramming
- Generation of cardiac mesoderm progenitor cells
- Cardiomyocytes exhibit functional properties
- Reprogramming doesnt generate pluripotent cells
- Direct reprogramming of fibroblasts to iNPCs
- Differentiated neurons have functional properties
- No pluripotent cell generation in iNPC process
- Reprogramming fibroblasts to definitive endoderm
- Further differentiation into pancreatic precursors
- Further differentiation into beta-like cells
- Transplantation of PPLC to diabetic mice
- Reprogramming fibroblasts into endothelial cells
- iEnd cells in peripheral arterial disease model
- The CASD reprogramming model
- CASD vs. conventional trans-differentiation
- Induction and long term expansion of NPCs
- Homogenous self-renewal of primitive NPCs
- Maintained neurogenic propensity after expansion
- In vivo engraftment
- DA neuron induction from expanded iNPCs
- Motor neuron induction from expanded iNPCs
- CD4 T cell lineage differentiation
- Ursolic acid specifically inhibit Th17 differentiation
- Ursolic acid functions as a RORүt antagonist
- Thank you
Topics Covered
- Stem cells
- Chemical biology
- Regeneration
- High throughput screening
- Self-renewal
- Differentiation
- Reprogramming
Talk Citation
Ding, S. (2014, March 5). A chemical approach to controlling cell fate [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/YWFG3491.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Sheng Ding has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Cell Biology
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Sheng Ding.
In my lecture today, I will
discuss with you our approach
of discovering and
using small molecules
to control and study stem
cell fate and functions.
0:15
First, let me tell you our
thinking on therapeutic strategies
toward regenerative medicine.
Certainly, we all know
cell-based therapy,
which is about transplanting
the right type of cells
in sufficient quantity
and where they are needed.
However, this approach has
a number of limitations.
Typically, the right
donor cells need
to be identified for immune
compatibility reasons.
The recipient often
needs to be conditioned
before receiving the transplant.
And often the cell
transplantation is
invasive and may not be effective.
Given our understanding
of stem cell biology,
improved approaches have been
developed, especially by using
small molecules in cell
cultures to direct cells
through vivo isolation,
in vitro differentiation,
or reprogramming, as well as our
ex vivo maintenance, expansion,
or activation for
enhanced in vivo activity.
On the other hand, we
do know that pretty
much in every different organ, there
are reserved stem in the progenitor
cells which normally function
to intend tissue homeostasis,
but also to respond
to disease and injury,
to regenerate to a small degree.
This is because the
regeneration signal
is typically not strong
or robust enough.
Therefore, an alternative
and perhaps more attractive
approach for regenerative
medicine would be developing
the conventional small molecule
drugs or biologics that
can be taken by patients
in more convenient ways.
And those molecules can act
in a tissue-specific manner
to modulate patient's own
cells to repair and regenerate
through various mechanisms including
cell activation, expansion,
differentiation, or even
in situ reprogramming.